Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00132626|
Recruitment Status : Completed
First Posted : August 22, 2005
Last Update Posted : February 21, 2007
|Condition or disease||Intervention/treatment||Phase|
|Parkinson's Disease Parkinsonian Syndrome||Procedure: [123I]ß-CIT and SPECT imaging||Phase 2|
The brain imaging is conducted at the Institute for Neurodegenerative Disorders in New Haven, Connecticut. The imaging procedure occurs over a two day period.
After a screening visit, including review of the potential subject's neurological history and a thorough neurologic exam, subjects are injected with [123I]ß CIT, an investigational radioactive material that localizes in the brain.
Twenty-four hours later study participants return to the Institute for Neurodegenerative Disorders where an investigational scanning procedure is used to obtain SPECT (single photon emission computed tomography) images of the brain.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||500 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Dynamic SPECT Imaging With [123I]ß-CIT in Patients With Parkinsonism|
|Study Start Date :||September 1992|
|Estimated Study Completion Date :||August 2005|
- CIT uptake: measurement of dopamine transporter density compared with the clinical severity of illness
- Measurement of variability of strital uptake of [123I]ß-CIT when more than one scan has occurred
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00132626
|Principal Investigator:||Kenneth Marek, MD||Institute for Neurodegenerative Disorders|